This article first appeared on GuruFocus. Hims & Hers Health (NYSE:HIMS) faces a more complicated growth path as regulatory pressure reshapes its weight-loss business, prompting JPMorgan to resume coverage at Neutral with a $32 price target. The target implies roughly 17% upside from the Sept. 10 close, but the bank wants clearer evidence that Hims can successfully transition from compounded GLP-1 drugs toward branded treatments without sacrificing margins. Warning! GuruFocus has detected 5 Warning Signs with HIMS. Is HIMS fairly valued? Test your thesis with our free DCF calculator.
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.